Share

News kindly supplied by Kresimir Babic

Bach Pharma, Inc. and Destum Partners, Inc. - Corporate Development Initiatives

FOR IMMEDIATE RELEASE
 
NORTH ANDOVER, Massachusetts – October 31, 2011 – Bach Pharma, Inc. (Bach), a privately held drug development company focused on therapeutics for homeostatic oxidative related diseases, announces the selection of Destum Partners, Inc. to identify, evaluate, and secure strategic partnerships for Monosodium Luminol (GVT®). GVT® is currently approved for use in the Commonwealth of Independent States (CIS) countries including Russia, and a number of Central and Eastern European (CEE) countries as a standard of care treatment for select cancer tumors, as an immunomodulator, an anti-inflammatory agent, and as an adjunct to chemotherapy and radiation treatments. A broad intellectual property estate owned by Bach covers compositions and uses of GVT® for the treatment of life threatening oxidative stress related diseases.

Monosodium Luminol has been studied extensively through approximately sixty five (65) human clinical trials in numerous therapeutic areas ranging from cancer therapy and wound healing, to treatments for diseases related to the central nervous system (CNS). While the therapeutic breadth is impressive, Destum Partners will focus on select strategic partnering opportunities. In particular, significant emphasis will be placed on securing partnerships for the advancement of the oncology and CNS applications of GVT® and its derivatives. Destum Partners is actively seeking partnerships to begin commercialization and distribution of GVT® in the CIS and select CEE countries, as well as partnerships focused on CNS related diseases.
Approvals are in place to annually treat over a half million cancer patients in the CIS countries alone, a very attractive market opportunity especially for an Eastern European partner. In CNS related diseases, GVT® is the subject of a phase I/II clinical study to treat ataxia-telangiectasia (A-T), a rare childhood genetic disorder, which currently has no effective treatment and leads to early complications of aging and death among its young patients. This study demonstrates strong pre-clinical support for its use in other CNS and/or Orphan diseases such as Parkinson’s, Amyotrophic Lateral Sclerosis (ALS) and Friedreich’s Ataxia.

Source/read more